OSE Immunotherapeutics
Clinical-stage biotech developing immune therapies for oncology and inflammation.
OSE | PA
Overview
Corporate Details
- ISIN(s):
- FR0012127173 (+2 more)
- LEI:
- 969500HIUWVGY6NZSM05
- Country:
- France
- Address:
- 22 BOULEVARD BENONI GOULLIN, 44200 NANTES
- Sector:
- Manufacturing
Description
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-09 08:00 |
MISE À JOUR DES MODALITÉS DE L’ASSEMBLÉE GÉNÉRALE
|
French | 178.6 KB | ||
| 2025-06-09 08:00 |
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
|
English | 184.3 KB | ||
| 2025-06-05 18:00 |
Informations relatives au nombre total de droits de vote et d’actions composan…
|
French | 196.4 KB | ||
| 2025-06-04 08:00 |
Ose Immunotherapeutics : Mise à disposition des documents préparatoires à l’Ass…
|
French | 174.9 KB | ||
| 2025-06-04 08:00 |
OSE Immunotherapeutics renforce sa stratégie de croissance : Accélération des …
|
French | 791.9 KB | ||
| 2025-06-04 08:00 |
Ose Immunotherapeutics : Documents made available to the shareholders for the c…
|
English | 222.3 KB | ||
| 2025-06-04 08:00 |
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of…
|
English | 290.7 KB | ||
| 2025-06-02 18:00 |
OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Va…
|
English | 333.0 KB | ||
| 2025-06-02 18:00 |
OSE Immunotherapeutics fait un point clinique sur Tedopi®, vaccin contre le can…
|
French | 311.0 KB | ||
| 2025-05-23 07:00 |
OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présente…
|
French | 293.3 KB | ||
| 2025-05-23 07:00 |
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Pre…
|
English | 264.6 KB | ||
| 2025-05-21 18:00 |
OSE Immunotherapeutics annonce une collaboration stratégique sur des technologi…
|
French | 282.7 KB | ||
| 2025-05-21 18:00 |
OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA …
|
English | 319.0 KB | ||
| 2025-05-06 18:00 |
Informations relatives au nombre total de droits de vote et d’actions composant…
|
French | 196.9 KB | ||
| 2025-05-05 18:30 |
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remi…
|
English | 282.0 KB |
Automate Your Workflow. Get a real-time feed of all OSE Immunotherapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OSE Immunotherapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OSE Immunotherapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-19 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,800.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-13 | N/A | Other | Sell | 6,369 | 45,879.09 EUR |
| 2024-06-03 | N/A | Other | Sell | 40,000 | 314,512.00 EUR |
Peer Companies
